TargetCancer Foundation

The specific purposes of the Organization are to raise awareness of and support for research into rare cancers, and to directly support patients and families facing rare cancers. This was accomplished in the fiscal year through the ongoing operation of a rare cancer precision medicine clinical trial, and through other programs. In 2020, TargetCancer Foundation launched a rare cancer precision medicine clinical trial called TCF-001 TRACK (Target Rare Cancer Knowledge). TRACK is a 400-patient clinical trial studying genomics and precision medicine in rare cancers, providing patients with critical personalized genomic data about their cancer and treatment recommendations from a panel of field leaders, and also generating rare cancer research data. TRACK is developed, sponsored and managed by TargetCancer Foundation, and is currently enrolling patients with rare cancers and cancer of unknown primary.In 2022, TargetCancer Foundation held two major scientific meetings- the Think Tank on Advancing Precision Medicine in Rare Cancers, and the Think Tank on Advancing Gastroesophageal Cancer Research. These unique, innovative meetings unite key stakeholders including clinicians, researchers, government, industry, and patients and advocates. These meetings are specifically designed to promote collaboration, information-sharing and idea generation in an effort to define research priorities, foster new collaborative efforts across institutions, and ultimately propel the field forward.